- Notice
Call for Participants] [Osaka Conference of the Japan Society for Hyperdisciplinary Research] Future Dementia Strategies - New Insights from Advances in Detection Methods / April 24, 2021, 15:30~@Osaka, Japan
2021.04.01
A panel discussion, "Future Dementia Strategies - New Insights from Advances in Detection Methods" (session partner: Sysmex Corporation), will be held within the Osaka Conference 2021 (Saturday, April 24, 2021) of the Society of Transdisciplinary Research hosted by LIVANESS.
Dementia, when severe, causes neuronal degeneration and cell death and is difficult to regenerate; in 2018, the FDA suggested the importance of preventive interventions. On the other hand, it is difficult to detect the disease in its early stages, and methods to detect signs in the early stages of the disease based on changes in brain anatomy and components in the blood have been continuously searched for, and some indicators are finally emerging. In this session, Mr. Aoyama of Splink Corporation, which aims for early detection of dementia with its unique MRI brain image analysis technology, Dr. Tomiyama of Osaka City University, which promotes prevention research through biomarker search and development of drugs and foods with anti-dementia effects, and Dr. Ltd., which is seeking approval for a blood test to measure amyloid-β in plasma, which has been reported to be associated with Alzheimer's disease, to discuss how the combination of technologies can change strategies for early detection, prevention and treatment of dementia.
We will have a program of discussions among researchers, start-ups, and large companies from a variety of perspectives, not limited to the themes of this session.
We are now accepting applications for auditing, so please join us.The information is available on the convention website (see below).
Future Dementia Strategies - New Insights from Advances in Detection Methods
Date: Saturday, April 24, 2021, 15:30-16:30
Location:Maruzen Intec Arena Osaka (3-1-40 Tanaka, Minato-ku, Osaka, 552-0005, Japan (in Hachimanya Park)
Details:https://hic.lne.st/conference/hic2021/
speaker
Sysmex Corporation
General Manager, Technology Strategy Div.
Kenji Tsujimoto(in Japanese history)Kenji Tsuchimoto(Mr.)
D. from the Graduate School of Pharmaceutical Sciences, Kyoto University. After working for pharmaceutical companies and venture capital firms, he joined Sysmex Corporation in 2011. After being involved in business strategy formulation and M&A at the Business Strategy Division, he has served as the General Manager of the Technology Strategy Division from 2017 to the present. In addition to formulating technology strategies and promoting technology strategies utilizing open innovation, he also focuses on bridging from technology to business. (BRIH-K, BRIH-K), which supports the utilization of bioresources such as blood from patients.The following is a list of the most common problems with the
Splink Corporation
Representative Director
Yuki Aoyama(in Japanese history)Aoayama(Mr.)
After graduating from Keio University Faculty of Law, joined Keyence Corporation. He was engaged in business development in Keyence's North American business, establishment of a Brazilian subsidiary, and management of a Mexican subsidiary. After that, he worked as an EiR (Entrepreneur in Residence) at a Silicon Valley VC firm, and established Sprink Corporation in January 2017, where he was appointed as Representative Director. Graduated from Dartmouth College's Graduate School of Business Administration (MBA), and will be a visiting researcher at the RIKEN Center for Bioscience and Biotechnology in 2019.The following is a list of the most common problems with the
Osaka City University Graduate School of Medicine
research professor
Takami Toyama(in Japanese history)Taka Tomiyama(Mr.)
Completed a master's degree at Tokyo Institute of Technology in 1986. After engaging in research and development of pharmaceuticals at Teijin Limited, he has been a faculty member at Osaka City University since 1998, currently a research professor at the Graduate School of Medicine. After discovering a new genetic mutation for Alzheimer's disease (Osaka mutation), developing model mice, and developing therapeutic tau antibodies, he is currently working on the development of prophylactic drugs and foods for dementia. Based on the results of his research, he established Cerebro Pharma, Inc. in 2017 and Medilab RFP, Inc. in 2018, aiming for commercialization within a few years.The following is a list of the most common problems with the
.
Leave a Nest Co., Ltd.
Executive Officer
Hiroyuki Takahashi
D. from Yokohama City University in 2009. D. in Science, focusing on creating new research projects between industry and young researchers, including the launch of the "Liberace Research Fund" for young researchers under the age of 40. In addition, he continues to organize the "Super Interdisciplinary Society," a place to generate new knowledge and seeds for research and development by combining individual knowledge, technology, and passion for problem solving without being bound by the framework of academia.
English 
Japanese